Company

Repare Therapeutics Inc.

Headquarters: Montreal, QC, Canada

Employees: 152

CEO: Mr. Lloyd Mitchell Segal

NASDAQ: RPTX +0.46%

Market Cap

$140.1 Million

USD as of July 1, 2024

Market Cap History

Repare Therapeutics Inc. market capitalization over time

Evolution of Repare Therapeutics Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Repare Therapeutics Inc.

Detailed Description

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306 which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Repare Therapeutics Inc. has the following listings and related stock indices.


Stock: NASDAQ: RPTX wb_incandescent

Details

Headquarters:

7210 Frederick-Banting

Suite 100

Montreal, QC H4S 2A1

Canada

Phone: 857 412 7018